Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Université de Montréal
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Blood Oxygenation
Study Overview
Brief Summary
Glaucoma is the second leading cause of blindness among seniors in Canada. It is often associated with an elevated intraocular pressure (IOP), but its exact mechanism is still largely unknown. Some studies have shown a link between glaucoma and changes in the amount of oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular veins among three different groups using a spectrophotometer. This instrument is linked to a camera and can measure the quantity of oxygen in the veins using different characteristics of the blood inside.
The groups of the study are: patients without glaucoma, patients suspected of glaucoma and patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost 0.004%, will only be administered to the groups suspected or diagnosed with glaucoma. Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten patients will be recruited into each group for a total of 30 patients in this study. All patients for the suspected or diagnosed groups will be recruited from the Jewish General Hospital. Subsequently all testing will be done at the École d'optométrie, Université de Montréal
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 45 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •good systemic health
- •irido-corneal angle open
- •intraocular pressure more than 18 mmHg
Exclusion Criteria
- •having cardiovascular problem
- •Hypertension or diabetes
- •under systemic medication for high blood pressure
- •had an ocular surgery in the past
Arms & Interventions
Newly diagnosed glaucoma
Treated with Travoprost (0.04%)
Intervention: travoprost (Drug)
Normal control
Normal patient placebo
Intervention: placebo (Drug)
Glaucoma suspect
Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
Intervention: placebo (Drug)
Outcomes
Primary Outcomes
Blood Oxygenation
Time Frame: 1 hour
For each subject, all the measurements will be done during an 1 hour appointment.
Secondary Outcomes
No secondary outcomes reported
Investigators
Pierre Forcier
Associate professor
Université de Montréal